Infantile atopic dermatitis: Factors driving steroid escalation :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Allergic comorbidities signal higher risk for topical steroid escalation in infantile eczema

Infantile atopic dermatitis Infantile atopic dermatitis
Infantile atopic dermatitis Infantile atopic dermatitis

What's new?

Children with infantile atopic dermatitis and existing atopic comorbidities are over 3 times more likely to require escalation to higher-potency topical corticosteroids.

Atopic dermatitis (AD, eczema) affects 15% to 20% of children globally, making primary care providers—pediatricians and family physicians—the true front line of initial care. Yet, real-world prescribing choices and early treatment trajectories for infants presenting with new-onset eczema have remained surprisingly obscure.

A single-center retrospective cohort study tracking 3,053 infants and toddlers (mean age 0.6 years; 54.4% male) sheds clear light on how primary care clinicians initially tackle AD—and which clinical clues signal a need for stronger intervention.

Baseline prescribing: A cautious approach or potential undertreatment?

Nearly one-third of the cohort (33.2%, n = 1,015) presented with at least one co-occurring atopic condition or complication. Among these, conjunctivitis was most frequent (41.8%), followed closely by allergic rhinitis (34.7%), general allergy (33.4%), asthma (28.8%), and secondary bacterial skin infections (6.7%).

While two-thirds of children (66.8%, n = 2,038) received a prescription at their index visit (V1)—totaling 3,043 distinct prescriptions—targeted topical anti-inflammatory agents were used sparingly:

  • Topical corticosteroids (TCS): Made up 48.4% of total initial prescriptions (1,472/3,043). Clinicians favored mild options: low-potency formulations dominated (71.5%, 1,053/1,472), while medium-potency (27.3%, 402/1,472) and high-potency agents (1.2%, 17/1,472) exhibited far less use.
  • Adjunctive & second-line therapies: Topical antifungals represented 4.4% of prescriptions (134/3,043) and oral antihistamines accounted for 4.0% (121/3,043). Topical calcineurin inhibitors were almost non-existent in this initial window (0.2%, 7/3043).

Because fewer than half of total prescriptions involved direct anti-inflammatory skin control, the investigators emphasize an urgent question for future research: Does this low initial prescribing rate reflect mild baseline disease, or are family practices under-treating early infantile eczema?

The escalation drivers

Among 1,261 kids with recorded follow-up between their first (V1) and second (V2) clinic visits, 6.2% (n = 78) adjusted their TCS potency level. Therapeutic escalation to a stronger steroid occurred in 5.2% of children, whereas 1.0% de-escalated to a milder agent.

Statistical modeling revealed a striking risk factor: infants presenting with pre-existing atopic comorbidities or complications faced more than three times the likelihood of requiring a potency step-up (odds ratio [OR] 3.15).

Key takeaway for practice

Underlying systemic allergic disease serves as an early warning sign for primary care clinicians. Recognizing coexisting allergic features during an infant's initial skin assessment can help clinicians anticipate treatment challenges, optimize initial treatment potency, and avoid delays in attaining successful anti-inflammatory control.

Source:

Pediatric Dermatology

Article:

Initial Management of Infantile Atopic Dermatitis in Primary Care Settings and Predictors of Topical Steroid Potency Escalation

Authors:

Moira Shea et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: